CASI Pharmaceuticals Inc (CASI) has a current Price-to-Book (P/B) ratio of NaN. Compared to its 3-year average P/B ratio of 2.62, the current P/B ratio is approximately NaN% higher. Relative to its 5-year average P/B ratio of 2.09, the current P/B ratio is about NaN% higher. CASI Pharmaceuticals Inc (CASI) has a Forward Free Cash Flow (FCF) yield of approximately NaN%. Compared to its 3-year average FCF yield of -8.68%, the current FCF yield is approximately NaN% lower. Relative to its 5-year average FCF yield of -27.72%, the current FCF yield is about NaN% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CASI competitors is 7.01, providing a benchmark for relative valuation. CASI Pharmaceuticals Inc Corp (CASI.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -60.54%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CASI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CASI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CASI currently overvalued or undervalued?

CASI Pharmaceuticals Inc (CASI) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -3.25. The fair price of CASI Pharmaceuticals Inc (CASI) is between -- to -- according to relative valuation method.

What is CASI Pharmaceuticals Inc (CASI) fair value?

CASI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CASI Pharmaceuticals Inc (CASI) is between -- to -- according to relative valuation method.

How does CASI's valuation metrics compare to the industry average?

The average P/S ratio for CASI's competitors is 7.01, providing a benchmark for relative valuation. CASI Pharmaceuticals Inc Corp (CASI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -60.54%, this premium appears unsustainable.

What is the current P/B ratio for CASI Pharmaceuticals Inc (CASI) as of Mar 03 2026?

As of Mar 03 2026, CASI Pharmaceuticals Inc (CASI) has a P/B ratio of NaN. This indicates that the market values CASI at NaN times its book value.

What is the current FCF Yield for CASI Pharmaceuticals Inc (CASI) as of Mar 03 2026?

As of Mar 03 2026, CASI Pharmaceuticals Inc (CASI) has a FCF Yield of NaN%. This means that for every dollar of CASI Pharmaceuticals Inc's market capitalization, the company generates NaN cents in free cash flow.

What is the current Forward P/E ratio for CASI Pharmaceuticals Inc (CASI) as of Mar 03 2026?

As of Mar 03 2026, CASI Pharmaceuticals Inc (CASI) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of CASI Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CASI Pharmaceuticals Inc (CASI) as of Mar 03 2026?

As of Mar 03 2026, CASI Pharmaceuticals Inc (CASI) has a Forward P/S ratio of NaN. This means the market is valuing CASI at $NaN for every dollar of expected revenue over the next 12 months.

CASI Valuation